Celcuity (NASDAQ:CELC) Releases Earnings Results, Misses Estimates By $0.13 EPS

Celcuity (NASDAQ:CELC) released its earnings results on Monday. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.13), Zacks reports.

Celcuity Trading Down 1.3 %

Celcuity stock opened at $10.11 on Tuesday. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65. Celcuity has a 12-month low of $8.53 and a 12-month high of $22.04. The firm has a market capitalization of $375.38 million, a price-to-earnings ratio of -3.87 and a beta of 0.65. The firm has a 50 day moving average of $11.18 and a 200 day moving average of $12.91.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on CELC shares. Needham & Company LLC reaffirmed a “buy” rating and set a $29.00 target price on shares of Celcuity in a report on Tuesday. HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of Celcuity in a report on Tuesday. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $30.17.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.